Hilary Calvert

6.5k total citations · 2 hit papers
79 papers, 5.0k citations indexed

About

Hilary Calvert is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hilary Calvert has authored 79 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 24 papers in Molecular Biology. Recurrent topics in Hilary Calvert's work include Lung Cancer Treatments and Mutations (19 papers), Cancer Treatment and Pharmacology (17 papers) and Colorectal Cancer Treatments and Studies (14 papers). Hilary Calvert is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Cancer Treatment and Pharmacology (17 papers) and Colorectal Cancer Treatments and Studies (14 papers). Hilary Calvert collaborates with scholars based in United Kingdom, United States and Italy. Hilary Calvert's co-authors include Henry S. Friedman, Tracy Kerby, Ruth Plummer, Adrian L. Harris, Stan B. Kaye, Alan V. Boddy, Richard H. Wilson, Malcolm Ranson, Helen Swaisland and Éric Raymond and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Hilary Calvert

79 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 683 citations Danny Rischin, Malcolm Ranson et al. Journal of Clinical Oncology profile →
Temozolomide and treatment of malignant glioma.

2000 590 citations Hilary Calvert et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hilary Calvert United Kingdom	31	2.6k	2.2k	1.5k	765	610	79	5.0k
Ruth Plummer United Kingdom	41	3.4k 1.3×	3.3k 1.5×	1.1k 0.7×	400 0.5×	688 1.1×	230	6.0k
Christian Dittrich Austria	33	1.6k 0.6×	1.4k 0.6×	833 0.5×	509 0.7×	664 1.1×	136	4.0k
Stephen R. Wedge United Kingdom	39	2.6k 1.0×	3.6k 1.7×	1.6k 1.0×	1.0k 1.3×	1.4k 2.4×	103	7.0k
Lowell L. Hart United States	37	3.5k 1.3×	1.7k 0.8×	2.2k 1.4×	267 0.3×	763 1.3×	127	5.5k
K. Mross Germany	37	3.1k 1.2×	2.1k 1.0×	1.0k 0.7×	256 0.3×	606 1.0×	148	5.2k
Ferry A.L.M. Eskens Netherlands	43	2.9k 1.1×	2.6k 1.2×	1.5k 1.0×	393 0.5×	1.2k 2.0×	161	6.4k
Sarah Danson United Kingdom	31	2.2k 0.8×	1.7k 0.7×	1.1k 0.7×	256 0.3×	485 0.8×	120	4.4k
Paul de Souza Australia	38	3.2k 1.2×	1.9k 0.8×	2.1k 1.3×	939 1.2×	1.3k 2.1×	152	6.2k
Neville Davidson United Kingdom	14	3.7k 1.4×	1.3k 0.6×	1.2k 0.8×	355 0.5×	793 1.3×	25	5.0k
Shom Goel United States	25	3.1k 1.2×	2.3k 1.0×	1.8k 1.2×	553 0.7×	1.5k 2.5×	71	5.8k

Countries citing papers authored by Hilary Calvert

Since Specialization

Citations

This map shows the geographic impact of Hilary Calvert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilary Calvert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilary Calvert more than expected).

Fields of papers citing papers by Hilary Calvert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hilary Calvert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilary Calvert. The network helps show where Hilary Calvert may publish in the future.

Co-authorship network of co-authors of Hilary Calvert

This figure shows the co-authorship network connecting the top 25 collaborators of Hilary Calvert. A scholar is included among the top collaborators of Hilary Calvert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilary Calvert. Hilary Calvert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Plummer, Ruth, Paul Lorigan, Ewan Brown, et al.. (2013). Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. British Journal of Cancer. 109(6). 1451–1459. 23 indexed citations

Porcelli, Letizia, Paola Mantuano, Nicola Silvestris, et al.. (2012). Synthetic Lethality to Overcome Cancer Drug Resistance. Current Medicinal Chemistry. 19(23). 3858–3873. 13 indexed citations

Arkenau, Hendrik‐Tobias, Ruth Plummer, L. Rhoda Molife, et al.. (2011). A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Annals of Oncology. 23(5). 1307–1313. 52 indexed citations

Calvert, Hilary & Amalia Azzariti. (2011). The clinical development of inhibitors of poly(ADP-ribose) polymerase. Annals of Oncology. 22. i53–i59. 39 indexed citations

Rustin, Gordon, Nicholas Reed, Gordon C. Jayson, et al.. (2011). A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Annals of Oncology. 22(11). 2411–2416. 23 indexed citations

Goodwin, Rachel, Giuseppe Giaccone, Hilary Calvert, Marinus W. Lobbezoo, & Elizabeth A. Eisenhauer. (2011). Targeted agents: How to select the winners in preclinical and early clinical studies?. European Journal of Cancer. 48(2). 170–178. 24 indexed citations

Yap, Timothy A., Laura Vidal, Jan Adam, et al.. (2010). Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 28(25). 3965–3972. 295 indexed citations

Pinkney, Michael, et al.. (2009). A Monoclonal Antibody for Detection of Folylpolyglutamate Synthetase in Paraffin Embedded Tissues. Hybridoma. 28(6). 415–421. 1 indexed citations

Vergote, Ignace, Hilary Calvert, Marek Kania, et al.. (2009). A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. European Journal of Cancer. 45(8). 1415–1423. 40 indexed citations

10.

Sarkaria, Jann N., Gaspar J. Kitange, C. David James, et al.. (2008). Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. Clinical Cancer Research. 14(10). 2900–2908. 291 indexed citations

11.

Drew, Yvette & Hilary Calvert. (2008). The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers. Annals of the New York Academy of Sciences. 1138(1). 136–145. 42 indexed citations

12.

Plummer, Ruth, Gerhardt Attard, Simon Pacey, et al.. (2007). Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers. Clinical Cancer Research. 13(20). 6187–6194. 198 indexed citations

13.

Latz, Jane E., Susumu Adachi, James T. Symanowski, et al.. (2007). PD4-3-4: Correlation of pemetrexed (PEM) NSCLC exposure-response relationships (ERRs) to clinical study results from western and Japanese patient populations. Journal of Thoracic Oncology. 2(8). S455–S456. 6 indexed citations

14.

Calvert, Hilary. (2003). Pemetrexed (Alimta): A promising new agent for the treatment of breast cancer. Seminars in Oncology. 30(2D). 2–5. 11 indexed citations

15.

Lacombe, Didier, P. Therasse, P. Fumoleau, et al.. (2003). Cancer Drug Development in Europe: A Selection of New Agents Under Development at the European Drug Development Network. Cancer Investigation. 21(1). 137–147. 3 indexed citations

16.

LoRusso, Patricia, Roy S. Herbst, Danny Rischin, et al.. (2003). Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.. PubMed. 9(6). 2040–8. 40 indexed citations

17.

Calvert, Hilary & Paul A. Bunn. (2002). Future directions in the development of pemetrexed. Seminars in Oncology. 29(2 Suppl 5). 54–61. 16 indexed citations

18.

Calvert, Hilary. (2002). Folate status and the safety profile of antifolates. Seminars in Oncology. 29(2). 3–7. 42 indexed citations

19.

Gore, Martin, Amit M. Oza, Gordon Rustin, et al.. (2002). A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. European Journal of Cancer. 38(1). 57–63. 82 indexed citations

20.

Smyth, John, Jan H.M. Schellens, Hilary Calvert, et al.. (2001). Activity of the dolastatin analogue, LU103793, in malignant melanoma. Annals of Oncology. 12(4). 509–511. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact